Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | MC4R | P32245 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | MC3R | P41968 | 1/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoterol SCHEMBL249376 | 0.98 | ADRB2 (1.00) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL5009 | 0.98 | ADRB2 (1.00) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL9971023 | 0.98 | ADRB2 (1.00) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL9971031 | 0.98 | ADRB2 (1.00) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL9971022 | 0.98 | ADRB2 (1.00) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL28315409 | 0.97 | ADRB2 (0.97) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL29378231 | 0.97 | ADRB2 (0.97) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL1604836 | 0.97 | ADRB2 (0.97) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL4307761 | 0.96 | ADRB2 (0.94) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 | |
| Fenoterol SCHEMBL15517852 | 0.94 | ADRB2 (0.92) | ADRB2CYP3A4MAPK1NPSR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024223428-A1 | PROCESS FOR PREPARING 5-{2-[BENZYL-(1-(4-HYDROXYPHENYL)-1-METHYLETHYL)AMINO]-1-HYDROXYETHYL}BENZENE-1,3-DIOL HEMIFUMARATE | INDUSTRIALE CHIMICA S.R.L. (IT) | 2024-10-31 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-116196298-A | Aerosol pharmaceutical composition containing glycopyrronium salt and preparation method and application thereof | 四川海思科制药有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-116194094-A | For using beta 2 Method and composition for preventing and treating myopia by adrenergic receptor agonist fenoterol hydrobromide and derivatives thereof | 纽约市哥伦比亚大学理事会 | 2023-05-30 | — | — | CN | claimed |
| CN-116173025-A | Aerosol pharmaceutical composition containing glycopyrronium salt and indacaterol salt, and preparation method and application thereof | 四川海思科制药有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230138414-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-05-04 | — | — | US | claimed |
| EP-4164607-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH FENOTEROL HYDROBROMIDE, A ß2- ADRENERGIC RECEPTOR AGONIST, AND DERIVATIVES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2023-04-19 | — | — | EP | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022132119-A1 | USE OF A PHARMACEUTICAL COMPOSITION IN THE TREATMENT OF NOVEL CORONAVIRUS DISEASE (COVID-19) IN PREGNANT WOMEN AND PATIENTS WITH IMMUNOPATHOLOGICAL CONDITIONS ACCOMPANIED BY CHRONIC DISEASES, FOR RESPIRATORY SUPPORT, AND METHOD OF USE | ТЫХОНИВСЬКА, Наталия Мыколаивна | 2022-06-23 | — | — | WO | claimed |
| WO-2021252626-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH FENOTEROL HYDROBROMIDE, A β2- ADRENERGIC RECEPTOR AGONIST, AND DERIVATIVES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-12-16 | — | — | WO | claimed |
| WO-1995005805-A1 | PROCESS FOR CONDITIONING SUBSTANCES | ASTRA AKTIEBOLAG (SE) | 1995-03-02 | — | — | WO | claimed |
| EP-0605578-A1 | PRESSURISED AEROSOL COMPOSITIONS. | FISONS PLC (GB) | 1994-07-13 | — | — | EP | claimed |
| EP-0536204-B1 | THE USE OF SOLUBLE FLUOROSURFACTANTS FOR THE PREPARATION OF METERED-DOSE AEROSOL FORMULATIONS | MINNESOTA MINING & MFG (US) | 1994-04-06 | — | — | EP | claimed |
| EP-0580648-A1 | PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES. | ASTRA AB (SE) | 1994-02-02 | — | — | EP | claimed |
| EP-0536204-A1 | THE USE OF SOLUBLE FLUOROSURFACTANTS FOR THE PREPARATION OF METERED-DOSE AEROSOL FORMULATIONS. | MINNESOTA MINING & MFG (US) | 1993-04-14 | — | — | EP | claimed |
| WO-1993005765-A1 | PRESSURISED AEROSOL COMPOSITIONS | FISONS PLC (GB) | 1993-04-01 | — | — | WO | claimed |
| EP-0534731-A1 | Pressurised aerosol compositions | FISONS plc (GB) | 1993-03-31 | — | — | EP | claimed |
| WO-1992018110-A1 | PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES | AKTIEBOLAGET ASTRA (SE) | 1992-10-29 | — | — | WO | claimed |
| EP-0508969-A1 | Process for conditioning of water-soluble substances | Astra Aktiebolag (SE) | 1992-10-14 | — | — | EP | claimed |
| WO-1992000062-A1 | THE USE OF SOLUBLE FLUOROSURFACTANTS FOR THE PREPARATION OF METERED-DOSE AEROSOL FORMULATIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-01-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138414-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA | SPHK2, HDAC2, SPHK1 | ADRB2 19/4885CYP3A4 2963/4885MAPK1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.